These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11800027)

  • 21. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
    Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
    Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.
    Pierson AS; Gibbs P; Richards J; Russ P; Eckhardt SG; Gonzalez R
    Invest New Drugs; 2002 Aug; 20(3):357-62. PubMed ID: 12201500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
    Van Laar ES; Weitman S; MacDonald JR; Waters SJ
    Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.
    Dick RA; Yu X; Kensler TW
    Clin Cancer Res; 2004 Feb; 10(4):1492-9. PubMed ID: 14977853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I population pharmacokinetics of irofulven.
    Urien S; Alexandre J; Raymond E; Brain E; Smith S; Shah A; Cvitkovic E; Lokiec F
    Anticancer Drugs; 2003 Jun; 14(5):353-8. PubMed ID: 12782941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
    Van Laar ES; Roth S; Weitman S; MacDonald JR; Waters SJ
    Anticancer Res; 2004; 24(1):59-65. PubMed ID: 15015576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
    van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
    Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status.
    Herzig MC; Liang H; Johnson AE; Woynarowska B; Woynarowski JM
    Breast Cancer Res Treat; 2002 Jan; 71(2):133-43. PubMed ID: 11883439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
    Staake MD; Kashinatham A; McMorris TC; Estes LA; Kelner MJ
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1836-8. PubMed ID: 26922141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
    Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
    Wang W; Waters SJ; MacDonald JR; Roth C; Shentu S; Freeman J; Von Hoff DD; Miller AR
    Anticancer Res; 2002; 22(2A):559-64. PubMed ID: 12014623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
    Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
    Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells.
    Woynarowski JM; Woynarowska BA; Trevino AV; Salinas R; Herman TS; Waters SJ; Macdonald JR
    Cancer Biol Ther; 2004 Nov; 3(11):1137-42; discussion 1143-4. PubMed ID: 15467441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
    Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
    Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.
    Woynarowska BAHigdon AL; Muñoz RM; Bushong P; Waters SJ
    Invest New Drugs; 2001; 19(4):283-91. PubMed ID: 11561687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
    Briasoulis E; Judson I; Pavlidis N; Beale P; Wanders J; Groot Y; Veerman G; Schuessler M; Niebch G; Siamopoulos K; Tzamakou E; Rammou D; Wolf L; Walker R; Hanauske A
    J Clin Oncol; 2000 Oct; 18(20):3535-44. PubMed ID: 11032596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
    Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.